Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest PTEN Stories

2014-04-01 23:27:42

Rajal B. Shah, MD, Director of Urologic Pathology for Miraca Life Sciences, presents a recent study on PTEN and ERG Biomarker Interpretation. Irving, Texas (PRWEB) April 01, 2014 Miraca Life Sciences, the nation’s largest independent anatomical pathology laboratory, is honored to present an abstract at the 2014 Meeting of the American Urological Association (AUA) May 16-21 in Orlando, Florida. Among other results, the study showed that both PTEN and ERG biomarkers demonstrate...

2013-11-14 08:33:06

Findings further demonstrate the validity of a multiple-technology approach to tumor profiling for cancer patients IRVING, Texas, Nov. 14, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present five tumor profiling studies at the 2013 Annual Meeting of the Association for Molecular Pathology (AMP), held this week in Phoenix, Ariz. Results were obtained using Caris' comprehensive tumor profiling...

2013-10-31 23:29:07

Learn how to leverage PTEN and ERG testing as a prognostic marker for more aggressive cancers. Dallas, Texas (PRWEB) October 31, 2013 In November, Miraca Life Sciences (MLS) will offer a series of webinars demonstrating the value of molecular markers, such as PTEN and ERG in the diagnosing and prognostication of prostate cancer. These molecular markers offer additional insight beyond what a traditional prostate biopsy can provide. PTEN is a prognostic marker that helps to identify...

2013-10-16 23:28:37

More accurate profiles can optimize outcomes through personalized therapy. Irving, TX (PRWEB) October 16, 2013 Since July, 2013, Miraca Life Sciences (MLS) has been providing a new genomic testing protocol that helps Urologists guide better treatment decisions and determine outcomes in prostate cancer patients. MLS says two important genetic abnormalities occur in 50-60 percent of prostate cancer patients: one is characterized by loss of a protective gene known as PTEN, and another by...

2013-10-10 23:24:20

An increased presence at LUGPA 2013 provides an opportunity to showcase Miraca's new solutions for healthier patients, and a healthier practice. Irving, TX (PRWEB) October 10, 2013 Miraca Life Sciences (MLS), the leading pathology services provider that collaborates to make patients and practices better, announced today that it will have a significant presence at the Annual Meeting for the Large Urology Group Practice Association (LUGPA), a conference offering roundtable discussions,...

2013-09-09 16:23:53

Highly sensitive test gives researchers a more sophisticated tool to assess PTEN protein expression in cancer cells PLEASANTON, Calif., Sept. 9, 2013 /PRNewswire/ -- As researchers push to develop more customized diagnostics and therapies for solid tumor cancers, they demand increasingly sensitive tests that offer reliable, reproducible analysis. Spring Bioscience, Inc. (Spring) today announced a new addition to its specialized portfolio of valuable antibodies for cancer research...

Mutation Increases Melanoma Risk In Redheads
2013-08-23 04:22:04

April Flowers for redOrbit.com - Your Universe Online A person’s hair color and skin tone is determined by their skin pigment. This pigment is influenced by the melanocortin-1 (MC1R) gene receptor. For the world’s redheads – one to two percent of the population – their coloration is accounted for by a mutation in MC1R. A team of researchers led by Beth Israel Deaconess Medical Center (BIDMC) and Boston University School of Medicine (BUSM) has revealed that the same MC1R mutation...

2013-07-26 11:44:47

Scientists at the Princess Margaret Cancer Centre have discovered a function of the tumor suppressor gene PTEN that helps explain why certain promising therapies fail in many cancer patients, a finding that could aid in delivering tailored, personalized cancer medicine based on an individual's genetics. The research, published online today in Science, "increases understanding of the molecular mechanisms of action of PTEN, which is known to be defective in as many as half of all advanced...

2013-07-09 21:18:34

Discovery promises new targets for cancer drug design Genetic mutations aren’t the only thing that can keep a protein called PTEN from doing its tumor-suppressing job. Johns Hopkins researchers have now discovered that four small chemical tags attached (reversibly) to the protein’s tail can have the same effect, and they say their finding may offer a novel path for drug design to keep PTEN working. In a report published on July 9 in the journal...

2013-06-06 23:03:05

A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer, according to scientists from the Icahn School of Medicine at Mount Sinai. New York, NY (PRWEB) June 06, 2013 A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer, according to scientists from the Icahn School of Medicine at Mount Sinai. The variant, called PTEN-long, may contribute to a...